Synthesis, Characterization and Evaluation of Thiourea Derivatives for Cytotoxicity of Breast Cancer
DOI:
https://doi.org/10.21070/ijhsm.v2i2.202Keywords:
MCF-7 Inhibition, Thiourea Derivatives, Rescovitine, Anticancer Agents, Kinase InhibitorsAbstract
Background: Breast cancer is the leading cause of death in women worldwide and the second most common cause in the US. Rescovitine a clinical CDK2 inhibitor has been studied as a potential anticancer agent in breast cancer. has a short half-life (2–5 h), necessitating new analogs with improved pharmacokinetics. Objective: To design and synthesize five thiourea derivatives (VIa–VIe) that mimic rescovitine selectivity and low toxicity, while addressing its pharmacokinetic limitations. Evaluation the cytotoxicity in MCF-7 breast cancer cells. Materials & Methods: Derivatives were synthesized by reacting substituted benzoic acids with SOCl2, followed by the formation of isothiocyanates (IIa–e). Subsequent reflux with 5-amino-1H-pyrazole-4-carbonitrile yielded the thioureas VIa–VIe. Characterization: Melting points, NMR (¹H/¹³C), FT-IR spectroscopy, and EI-MS. antiproliferative activity against MCF-7 cell (MTT assay, IC₅₀), compared to rescovitine. Results: VIa and VIe showed best MCF-7 inhibition (93.77%, IC₅₀ = 123.64 μM; 94.55%, IC₅₀ = 118.49μM) vs. rescovitine (97.33%, IC₅₀ = 20.27μM). VIe (4-F substituent) and VIa (unsubstituted) exhibited strongest cytotoxicity against. All compounds complied with Lipinski’s Rule of Five (0 violations) and showed excellent GI absorption but no BBB permeability. Electronic substituents (e.g., F in VIe) enhanced the activity, while steric groups (e.g., CH₃ in VIb) reduced the efficacy. Conclusion: VIa and VIe emerged as lead candidates with cytotoxicity comparable to that of rescovitine. Fluorine substitution (VIe) optimized the activity, highlighting structure-activity relationships for future to get more potent molecules.
Highlights:
-
Lead Compounds Identified: VIa and VIe demonstrated strong antiproliferative activity in MCF-7 cells, approaching that of rescovitine, despite higher IC₅₀ values.
-
Structure-Activity Relationship (SAR): Electron-withdrawing substituents like fluorine (VIe) enhanced cytotoxicity, while bulky groups reduced efficacy.
-
Pharmacokinetics Advantage: All synthesized compounds complied with Lipinski’s Rule and exhibited excellent GI absorption—supporting their potential as orally available anticancer agents.
Keyword: MCF-7 Inhibition, Thiourea Derivatives, Rescovitine, Anticancer Agents,
.
References
[1] H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray, “Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries,” CA: A Cancer Journal for Clinicians, vol. 71, pp. 209–249, 2021.
[2] E. A. Mohmmed, S. S. Ramadan, A. S. El-Saiid, and W. G. Shousha, “Frequency and Clinical Features of Over-Expressed HER2 in Egyptian Breast Cancer Women Patients,” The Egyptian Journal of Hospital Medicine, vol. 85, pp. 3431–3435, 2021.
[3] Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), “Effects of Radiotherapy and of Differences in the Extent of Surgery for Early Breast Cancer on Local Recurrence and 15-Year Survival: An Overview of the Randomised Trials,” The Lancet, vol. 366, pp. 2087–2106, 2005.
[4] F. Chen, Z. Du, W. Yuan, L. Lu, and M. Li, “Evolution in Medicinal Chemistry of Sorafenib Derivatives for Hepatocellular Carcinoma,” European Journal of Medicinal Chemistry, vol. 179, pp. 916–935, 2019.
[5] Y. H. Chia, M. J. Ellis, and C. X. Ma, “Neoadjuvant Endocrine Therapy in Primary Breast Cancer: Indications and Use as a Research Tool,” British Journal of Cancer, vol. 103, pp. 759–764, 2010.
[6] Z. Momenimovahed and H. Salehiniya, “Incidence, Mortality and Risk Factors of Cervical Cancer in the World,” Biomedical Research and Therapy, vol. 41, pp. 1795–1811, 2017.
[7] Z. Ghoncheh, M. Pakzad, H. S. Hasanpour, and H. Salehiniya, “Incidence and Mortality of Uterine Cancer and Relationship with Human Development Index in the World,” Çukurova Medical Journal, vol. 42, pp. 233–240, 2017.
[8] J. R. Benson and I. Jatoi, “The Global Breast Cancer Burden,” Future Oncology, vol. 2, pp. 697–702, 2012.
[9] J. Ferlay, I. Soerjomataram, and F. Bray, “GLOBOCAN 2012 v1.0: Cancer Incidence and Mortality Worldwide – IARC Cancer Base No. 11,” International Agency for Research on Cancer, Lyon, France, 2013.
[10] M. Zendehdel, F. Nahvijou, and A. Fakhrejahani, “Subtypes of Benign Breast Disease as a Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis Protocol,” Iranian Journal of Medical Sciences, vol. 43, pp. 1182–1189, 2018.
[11] D. M. Parkin and L. M. Fernández, “Use of Statistics to Assess the Global Burden of Breast Cancer,” The Breast Journal, vol. 6, no. S1, pp. S70–S80, 2006.
[12] N. Mavaddat and P. D. P. Pharoah, “Prediction of Breast Cancer Risk Based on Profiling with Common Genetic Variants,” Journal of the National Cancer Institute, vol. 107, 2015.
[13] Z. Khakbazan, F. Taghipour, and H. Rahimzadeh, “Help Seeking Behavior of Women with Self-Discovered Breast Cancer Symptoms: A Meta-Ethnographic Synthesis of Patient Delay,” PLoS ONE, vol. 9, no. 12, 2014.
[14] M. N. George, D. Constantin, and T. O. Octavian, “New Potential Antitumor Pyrazole Derivatives: Synthesis and Cytotoxic Evaluation,” International Journal of Molecular Sciences, vol. 14, pp. 21805–21818, 2013.
[15] P.-C. Lv, H. Li, M.-Y. Sun, and H.-L. Zhu, “Synthesis and Biological Evaluation of Pyrazole Derivatives Containing Thiourea Skeleton as Anticancer Agents,” Bioorganic & Medicinal Chemistry, vol. 18, pp. 4606–4614, 2010.
[16] S. Y. Abbas, R. A. Al-Harbi, and M. A. S. El-Sharief, “Synthesis and Anticancer Activity of Thiourea Derivatives Bearing a Benzodioxol Moiety with EGFR Inhibitory Activity, Apoptosis Assay and Molecular Docking Study,” European Journal of Medicinal Chemistry, vol. 198, p. 112363, 2020.
[17] U. Asghar, A. K. Witkiewicz, N. C. Turner, and E. S. Knudsen, “The History and Future of Targeting Cyclin-Dependent Kinases in Cancer Therapy,” Nature Reviews Drug Discovery, vol. 14, pp. 130–146, 2015.
[18] S. Blagden and J. Bono, “Drugging Cell Cycle Kinases in Cancer Therapy,” Current Drug Targets, vol. 6, pp. 325–335, 2005.
[19] D. C. Kim, M. J. Seo, Y. R. Lee, J. Y. Kim, and K. R. Lee, “New Thiourea Derivatives as Potential Antitumor Agents,” European Journal of Medicinal Chemistry, vol. 38, pp. 525–532, 2003.
[20] J. Vesely, M. Havlícek, J. Strnad, and M. Marek, “Inhibition of Cyclin-Dependent Kinases by Purine Analogues,” European Journal of Biochemistry, vol. 224, pp. 771–786, 1994.
[21] A. T. F. Al-Halbosy, M. A. Ameen, A. H. Al-Karkhi, and S. M. Jabir, “Thiourea Derivative Metal Complexes: Spectroscopic, Anti-Microbial Evaluation, ADMET, Toxicity, and Molecular Docking Studies,” Inorganics, vol. 11, no. 10, p. 345, Oct. 2023.
[22] P. N. Nelson and W. H. Mulder, “Thermodynamic and Kinetic Models for Acid Chloride Formation: A Computational and Theoretical Mechanistic Study,” Journal of Molecular Graphics and Modelling, vol. 118, p. 108298, May 2022.
[23] W. Carruthers and I. Coldham, Modern Methods of Organic Synthesis, 4th ed., Cambridge, UK: Cambridge University Press, 2004.
[24] N. Agerbirk, A. Olsen, and B. Christensen, “Derivatization of Isothiocyanates and Their Reactive Adducts for Chromatographic Analysis,” Phytochemistry, vol. 65, pp. 803–814, 2004.
[25] A. Neacsu, G. I. Stanciu, and D. Marinescu, “DFT Studies on Physicochemical Properties and Spectral Data of 2-Thiophene Carboxylic Acid Thiourea Derivatives,” Chemistry Proceedings, vol. 16, p. 27, Nov. 2024.
[26] S. Cherukupalli, R. S. Reddy, and S. P. Babu, “An Insight on Synthetic and Medicinal Aspects of Pyrazolo[1,5-a]pyrimidine Scaffold,” European Journal of Medicinal Chemistry, vol. 138, pp. 1002–1028, 2017.
[27] M. R. Maddani and K. R. Prabhu, “A Mild and Efficient Copper-Catalyzed Synthesis of Substituted 1,2,3-Triazoles Using Alcohols as Traceless Activating Groups,” The Journal of Organic Chemistry, vol. 75, pp. 2327–2332, 2010.
[28] M. P. Pollastri, “Overview on the Rule of Five,” Current Protocols in Pharmacology, vol. 49, pp. 1–9, Jun. 2010.
[29] E. T. Ali, H. N. K. Al-Salman, K. H. Rasool, M. S. Jabir, T. R. Ghimire, F. H. Shari, H. H. Hussein, A. A. Al-Freji, G. M. Sulaiman, A. A. K. Khalil, E. M. Ahmed, and M. T. A. Soliman, “2-(Benzhydryl Sulfinyl)-N-sec-butylacetamide Isolated from Fig Augmented Trastuzumab-Triggered Phagocytic Killing of Cancer Cells Through Interface with Fcγ Receptor,” Natural Product Research, vol. 37, no. 21, pp. 3815–3823, 2023.
[30] E. A. Abdelsalam, M. M. Ismail, A. A. Ghaly, M. A. S. El-Sharief, and S. A. M. Abood, “Discovery of Novel Thiazolyl-Pyrazolines as Dual EGFR and VEGFR Inhibitors Endowed with In Vitro Antitumor Activity Towards Non-Small Cell Lung Cancer,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 118, p. 109115, Oct. 2022.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Karrar Talib Awad, Dr. Hussein Nasser AL-Salman, Dr. Mazin Abed Al Ghani Najm
This work is licensed under a Creative Commons Attribution 4.0 International License.
